Trial Profile
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REGEN; REGENERATE
- Sponsors Intercept Pharmaceuticals
- 11 Feb 2024 This trial has been completed in Sweden (End Date: 15 Sep 2023), according to European Clinical Trials Database record.
- 11 Jan 2024 This trial has been completed in Hungary,according to the European Clinical Trials Database record.
- 31 Dec 2023 This trial has been completed in Finland,according to the European Clinical Trials Database record.